Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06907511 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06907511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 17, 2025
Completion date
December 1, 2026
Enrollment
720 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, pandemic influenza immunization